Vinati Organics Limited — Q4 FY25 earnings call

Call held 16 May 2025

Management summary

Vinati Organics delivered a strong performance in FY25, characterized by robust volume growth in its core ATBS and emerging Antioxidant segments. Despite a sharp decline in the IBB business, the company successfully expanded its margins and profitability. Management remains highly optimistic, providing aggressive growth guidance for the Antioxidant business and maintaining a steady outlook for its market-leading ATBS position.

Highlights

  • Consolidated Revenue for FY25 grew 18% YoY to ₹2,292 crores, driven by strong volume growth in ATBS and Antioxidants.

  • EBITDA for the full year rose 23% to ₹625 crores, with margins improving to approximately 27.2%.

  • PAT registered a 25% YoY increase, reaching ₹405 crores for FY25.

  • The ATBS segment exhibited 30% volume-driven growth in FY25; Phase 1 capacity expansion (25-30%) is on track for June 2025.

  • Antioxidant (AO) revenue surged 70% in FY25 to ₹210+ crores, with a target of ₹800-850 crores for FY26.

  • Management guided for a 20% Revenue CAGR over the next three years, supported by new product launches and capacity expansions.

  • Capital expenditure of ₹400 crores was allocated in FY25, with a further ₹360 crores earmarked for FY26.

  • IBB segment faced significant headwinds, witnessing a 27% revenue decline due to specific demand-side challenges.

Concerns

  • IBB Segment Decline

Key financials

  1. Revenue ₹2,292 Cr +18%YoY
  2. EBITDA ₹625 Cr +23%YoY
  3. PAT ₹405 Cr +25%YoY
  4. EBITDA Margin 27.2%

What they filed

Q1 FY27: revenue up 28.4%, net profit up 4.8% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue553 522 648 542 550 −1%531 +2%604 −7%696 +28%
EBITDA134 142 180 160 167 +25%157 +11%170 −6%170 +6%
Net profit104 94 123 104 115 +11%101 +7%124 +1%109 +5%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • ATBS
    35% Revenue Share30% Volume Growth
  • Butyl Phenol
    15% Revenue Share26% Growth
  • Antioxidants
    10% Revenue Share70% Revenue Growth
  • IBB
    11% Revenue Share-27% Revenue Growth

Guidance & targets

Revenue

  • Revenue CAGR Revenue · next 3 years · High confidence 20%
    Over the next three years, we've projected 20% CAGR in revenue supported by our leadership in ATBS, steady performance in butyl phenols and strong expansion in antioxidants.

    — Kaviraj Devaraj, Vice President – Corporate Finance

  • Antioxidant Revenue Revenue · FY26 · High confidence ₹800-850 crores
    Yes. So this year, we did about INR600 crores in FY '26, we should do between INR800 crores to INR850 crores, all coming from antioxidant growth.

    — Vinati Saraf Mutreja, Managing Director

  • VOPL Revenue Revenue · FY26 · Medium confidence ₹100+ crores
    And I think if I have to give a number, then probably we would be looking at INR100-odd crores kind of revenue coming in from VOPL in FY '26.

    — Kaviraj Devaraj, Vice President – Corporate Finance

Margin

  • EBITDA Margin Margin · FY26 · High confidence 26-27%
    No, I think over a long term period of 3 to 5 years, 26% - 27% EBITDA margin is what is sustainable in a B2B manufacturing business specialty chemical business.

    — Vinati Saraf Mutreja, Managing Director

Capex

  • FY26 Capital Expenditure Capex · FY26 · High confidence ₹360 crores
    Looking ahead, we have year marked across INR360-odd crores for FY'26 capex, ensuring continued investment in expansion, innovation and operational efficiency.

    — Kaviraj Devaraj, Vice President – Corporate Finance

Risks & concerns

  • IBB Segment Decline

    high

    IBB witnessed a 27% decline in FY25 due to specific demand-side challenges in the end-user industry.

    Management acknowledged

  • China/Singapore Import Competition

    medium

    Antioxidant business faces pricing pressure from imports, though management believes domestic qualification provides a competitive edge.

    Both acknowledged

  • Capacity Utilization Ramp-up

    medium

    Analysts questioned the ramp-up of the 50% ATBS expansion; management claims they are currently oversold.

    Analyst downplayed

Areas of evasion (1)

  • Specific R&D spend quantification was avoided, citing it as a 'strategy' rather than a number.

Q&A highlights

3 direct
ATBS Capacity Commitment Direct
Presently, we're oversold and there is a backlog of orders, we should be able to fill the new capacity coming in Phase 1 as soon as we start just given our order book and the pending orders.

Confirms that the 50% capacity expansion is backed by immediate demand rather than speculative growth.

Asked by Naushad Chaudhary, Aditya Birla

Antioxidant Pricing and Competition Direct
There is imports coming from China, from Singapore... but we are also able to... now our products have been accepted... and the major customers are very keen to work with our domestic suppliers.

Addresses the 'China dumping' risk, suggesting that domestic qualification and reliability are helping Vinati win contracts despite price competition.

Asked by Keyur Pandya, ICICI Prudential Life Insurance

VOPL Teething Issues and Profitability Direct
In VOPL FY25 there is a loss. In that INR12 crores is the depreciation and INR4 crores [expenses]. So, that production and expenses in VOPL you can see the consolidated and standalone difference.

Quantifies the initial drag from the new subsidiary and clarifies that the loss is primarily due to non-cash depreciation and initial setup costs.

Asked by Naushad Chaudhary, Aditya Birla

2 min read 5 chapters

Detailed narrative

ATBS Expansion and Market Dominance

Vinati Organics is expanding its ATBS capacity by 50% in two phases to meet surging demand from the oil and gas sector, particularly for enhanced oil recovery. Phase 1, adding 25-30% capacity, is expected to be operational by June 2025 and is already backed by a backlog of orders. Management notes that the application of ATBS-based polymers is becoming more efficient in oil extraction, driving structural demand growth.

Antioxidant Business as a Growth Engine

The Antioxidant (AO) segment is emerging as a primary growth driver, with revenue increasing from ₹120 crores in FY24 to over ₹210 crores in FY25. Management has set an aggressive target of ₹800-850 crores for FY26, banking on increased capacity utilization (expected to rise from 50% to 90%) and new product qualifications with major domestic customers. This segment is expected to contribute significantly to the company's 20% CAGR target.

VOPL Subsidiary and Product Diversification

The Veeral Organics (VOPL) subsidiary is undergoing a ₹500 crore capex program, with ₹250 crores already invested. While it faced initial teething troubles and a small loss in FY25, it is expected to generate ₹100+ crores in revenue in FY26. New products like anisole, 4-MAP, and TAA are scheduled for introduction in Q2 and Q3 of FY26, targeting diverse applications from pharmaceuticals to personal care.

Margin Sustainability and Operational Efficiency

Despite the introduction of newer products and potential pricing pressure in the AO segment, management remains confident in maintaining EBITDA margins between 26% and 27%. This sustainability is attributed to the company's B2B manufacturing model, vertical integration (such as backward integration into Anisole), and operational efficiencies. The company also highlighted its 32.5 MW solar capacity as a contributor to cost management.

Segmental Headwinds in IBB

The IBB (Isobutyl Benzene) segment, historically a core product, saw a significant 27% decline in FY25. Management attributed this to specific demand-side challenges rather than competitive loss. While other segments like Butyl Phenol grew by 26%, the IBB decline highlights a shift in the company's revenue mix toward ATBS and Antioxidants, which now collectively represent a larger portion of the portfolio.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls